| アブストラクト | Introduction: Patients under immunotherapies were excluded from the pivotal trials of vaccinations against the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), and no population-level data on disease outcomes such as case fatality rates in relation to vaccination coverage exist. Our study aims to fill this gap by investigating whether CFRs in patients with immunotherapies decrease with increasing vaccination coverage in the total population. Methods: We combined aggregated open source data on COVID-19 vaccination coverage from "Our World in Data" with publicly available anonymized COVID-19 case reports from the FDA Adverse Event Reporting System to compute COVID-19 CFRs for patients under immunotherapy at different vaccination coverage levels in the total population. CFRs at different vaccination coverage levels were then compared to CFRs before vaccination campaign start. Results: While we found an overall decrease in CFRs on population level with increasing vaccination coverage, we found no decrease in people using anti-CD20 or glucocorticoids. Discussion: Risk-mitigation strategies on an individual- and population-level are thus still needed to lower the probability of fatal SARS-CoV2 infection for these vulnerable populations. |
|---|
| ジャーナル名 | Frontiers in pharmacology |
|---|
| Pubmed追加日 | 2023/7/3 |
|---|
| 投稿者 | Salmen, Anke; Marti, Stefanie; Hoepner, Andreas G F; Chan, Andrew; Hoepner, Robert |
|---|
| 組織名 | Department of Neurology, Inselspital, Bern University Hospital and University of;Bern, Bern, Switzerland.;Department of Banking and Finance, Michael Smurfit Graduate Business School,;University College Dublin, Dublin, Ireland.;Department for Financial Stability and Capital Markets (DG FISMA), Platform for;Sustainable Finance, European Commission, Brussels, Belgium. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37397473/ |
|---|
